---
figid: PMC9549728__EMMM-14-e15705-g011
pmcid: PMC9549728
image_filename: EMMM-14-e15705-g011.jpg
figure_link: /pmc/articles/PMC9549728/figure/emmm202215705-fig-0005/
number: Figure 5
figure_title: Targeting the EGFR/MAPK pathway at different levels of the signaling
  cascade
caption: AScheme of EGFR/MAPK signaling pathway and targeting inhibitors.B–EDrug response
  curves upon treatment with inhibitors for (B) EGFR (afatinib and gefitinib), (C)
  B‐RAF (LY3009120, TAK‐632, vemurafenib, dabrafenib), (D) MEK1/2 (selumetinib and
  binimetinib) and (E) ERK1/2 (ravoxertinib and ulixertinib) (biological replicates
  n = 3, data are shown as mean ± SD).
article_title: Sensitivity towards HDAC inhibition is associated with RTK/MAPK pathway
  activation in gastric cancer.
citation: Therese Seidlitz, et al. EMBO Mol Med. 2022 Oct;14(10):e15705.
year: '2022'

doi: 10.15252/emmm.202215705
journal_title: EMBO Molecular Medicine
journal_nlm_ta: EMBO Mol Med
publisher_name: John Wiley and Sons Inc.

keywords:
- gastric cancer
- HDACi
- MAPK
- organoids
- Cancer
- Signal Transduction

---
